Seres Therapeutics

$7.51 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Seres Therapeutics

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens.

Stock Analysis

last close $7.51
1-mo return -12.7%
3-mo return 23.1%
avg daily vol. 820.47T
52-week high 29.9
52-week low 5.41
market cap. $738M
forward pe -
annual div. -
roe -18.6%
ltg forecast -
dividend yield -
annual rev. $155M
inst own. 82.8%
baraka

Subscribe now for daily local and international financial news

Subscribe